Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
'2020 performance to exceed market expectations' - as stated in RNS of June 24, ' are expected to deliver a net profit for the year significantly above market expectations.
The Board looks forward to providing a further update to shareholders for the year to 30 June 2020 in the week commencing 13 July 2020.'
.........so that's in about 10 trading days time. Should be interesting.........
Commercialising their graphene inks in a huge market with the help of a billion pound Thai company....and this share used to be over £2.......
or maybe HAYD.........
I'm very happy that our small £7m mcap company is being paid upfront fees by an over £1bn mcap Thai petrochemicals company to collaborate on a market that is anticipated to be worth almost $5bn by 2023.....as the IRPC VP said, ' working closely with Haydale will enable us to capture great opportunity in IoT megatrend."....and as RH69 has said this share was over £2.00 only 4 years ago........
Well they certainly deliver profit...........
How many therapeutics are being tested in relation to Covid-19? I have done a fair amount of research on this disease and it seems that regarding consistently positive potential then its Remdesivir.....and us! With Sir Patrick Vallance saying twice in the Covid-19 update yesterday that therapeutics are the way forward, and that a vaccine will take quite a while, plus all the evidence that interferon is actively being tested and used, then I think this share will start to move up towards the end of the month in expectation of good results from Covid-19 hospital trials....and then there are the COPD results of course......
With thanks to PaulFG below:
One of the stand out quality metrics for Allergy Therapeutics is that it passes 6 of the 9 financial tests in the Piotroski F-Score. The F-Score is a world-class accounting-based checklist for finding stocks with an improving financial health trend. A good F-Score suggests that the company has strong signs of quality.
Fair price
While quality is important, no-one wants to overpay for a stock, so an appealing valuation is vital too. With a weaker economy, earnings forecasts are unclear right across the market. But there are some valuation measures that can help, and one of them is the Earnings Yield.
Earnings Yield compares a company's profit with its market valuation (worked out by dividing its operating profit by its enterprise value). It gives you a total value of the stock (including its cash and debt), which makes it easier to compare different stocks. As a percentage, the higher the Earnings Yield, the better value the share.
A rule of thumb for a reasonable Earnings Yield might be 5%, and the Earnings Yield for Allergy Therapeutics is currently 21.3%.
In summary, good quality and relatively cheap valuations are pointers to those stocks that are some of the most appealing to contrarian value investors. It's among these shares that genuine mis-pricing can be found. Once the market recognises that these quality firms are on sale, those prices often rebound.
Has this Company been totally overlooked by the market? Results to Dec 2019 give strong cash position of £40m and trading update RNS today states: 'Reported revenues for the year ended 30 June 2020 are expected to be at least 4% ahead of last year in constant currency terms. A programme of operating cost efficiencies, together with the timing of the planned research and development expenditure over the 3 years to June 2022, are expected to deliver a net profit for the year significantly above market expectations.
The Board looks forward to providing a further update to shareholders for the year to 30 June 2020 in the week commencing 13 July 2020.'
Could be a decent climb up to mid July in expectation of a further positive update.......
Just posted this on the MWG board as well:
Interesting piece in Saturday's Times (apologies if already posted) which could expand on MWG's work in Italy:
Sewage Study finds virus was in Italy last year. Coronavirus was in Italy in mid-December....a study of sewage water has found. Samples taken in Turin and Milan on Dec 18 contained traces of the virus.......'After the outbreak we were testing sewage for the virus and realised we could check back in time by analysing old frozen samples we held on to'.....Sufferers are thought to shed the virus in their faces from the moment they are infected, days before they show symptoms,meaning sewage testing could spot outbreaks up to two weeks before doctors.....'we are now planning continual sewage testing in Italian tourist towns on the Adriatic coast from July 1 ahead of national testing in the autumn to catch a possible second wave.....'
Interesting piece in Saturday's Times (apologies if already posted) which could expand on MWG's work in Italy:
Sewage Study finds virus was in Italy last year. Coronavirus was in Italy in mid-December....a study of sewage water has found. Samples taken in Turin and Milan on Dec 18 contained traces of the virus.......'After the outbreak we were testing sewage for the virus and realised we could check back in time by analysing old frozen samples we held on to'.....Sufferers are thought to shed the virus in their faces from the moment they are infected, days before they show symptoms,meaning sewage testing could spot outbreaks up to two weeks before doctors.....'we are now planning continual sewage testing in Italian tourist towns on the Adriatic coast from July 1 ahead of national testing in the autumn to catch a possible second wave.....'
Have been unable to buy anything over £500 worth all morning......
Interview this morning with Matt Han**** on BBC Breakfast where he emphasised that Dexamethasone was just for treating patients that had been admitted to hospital and confirming (as Sir Patrick Vallance did last night on CV update) that he was hopeful of other treatments in the pipeline that would help patients from having to go into hospital....and he looked extremely relaxed. So what other treatments are there out there that could reduce the possibility of patients having to go into hospital?.....well I can think of one......
On CV update tonight, Sir Patrick talking about Dexamethasone: 'This is the start of something important.......this is the start of other drugs that might be added on top of it to make an even bigger effect in due course we hope.'
Personally I don't think there'll be any drop in SNG share price tomorrow.......
So off the top of my head over the last 3 months we have had:
- Testing for SNG-001 starts in hospital at end of March results due in 8 weeks
- testing extended to at home testing results due July
- In April WHO includes interferon in conjunction with Remdesivir as one of only 5 treatments being tested
- Marsden quoted as saying “ this could be our time”
- AZN renews relationship with Soton hospital
- Daily Mail and Sun talk of a vaccine delivered via an inhaler being developed by AZN
- continued search for volunteers in the Soton area
- Marsden quoted a saying SNG-001 could prevent a bad second week after being infected by Covid-19
- Eleanor Fish, Professor of Immunology at University of Toronto. has been advocating strongly the use of Interferon in the treatment of Covid-19 and other respiratory diseases
- Newcastle GP on Friday when talking about the dangers of COPD being a danger to patients being infected with Covid-19
I have no doubt missed many other positive references to anecdotal evidence of interferon being key in boosting the bodies defence against Covid-19........ and then we have a classic 55% retrace from recent highs coinciding with Link Fund holding being bought by Acacia coincidentally at the placing price of 35p...... and then on Friday a very brief dip below 35p and a surge up in the afternoon with many NT periods.
Do I think this week will be a positive one......yep!
So off the top of my head over the last few months we have:
- Marsden “This could be our time“
- Testing started end of Mar
“In response to any and all viruses, the very first we do is make interferons. That, if nothing else, should tell you they are important. In addition, viruses have evolved to very specifically block interferon production. So coming in with interferon has the potential to override or swing the balance in favor of the host,” she explained.
Dr. Fish noted that the biggest fear with interferon is the potential to generate a “cytokine storm,” but there is “absolutely no evidence of that” from the SARS outbreak in Toronto or in COVID-19 patients. “If anything, the evidence was in the other direction, that we reduce the inflammatory response. Fear of cytokine storm I really think needs to be put to bed once and for all,” Dr. Fish said.
Why inhaled interferon in this study? “We went with what we could mobilize quickly and in Wuhan that was nebulized interferon,” Dr. Fish said. It’s unclear now which route of administration is going to be most efficient. “We are doing trials now to answer that.”
Dr. Fish also sees a potential prophylactic role for interferon for healthcare workers, others severely at risk, the elderly, the immunocompromised, and post-exposure individuals.
This has probably been posted before, so apologies for those that have read it already:
BIOTECHNOLOGYMAY 20, 2020 / 3:41 PM / 25 DAYS AGO
Interferon therapy may speed recovery from COVID-19
Megan Brooks
4 MIN READ
NEW YORK (Reuters Health) - Treatment with the antiviral interferon alfa-2b (IFN-a2b) appears to speed up virus clearance and lower levels of key inflammatory markers in patients with COVID-19, according to an exploratory study conducted in Wuhan, China.
This study provides “the first compelling evidence of a potential treatment that is approved and we have decades of experience with,” Dr. Eleanor Fish of the Toronto General Hospital Research Institute and the University of Toronto Department of Immunology, in Canada, told Reuters Health by phone.
In a paper in Frontiers of Immunology, Dr. Fish and colleagues report the clinical course of 77 adults with confirmed COVID-19 who were treated with inhaled IFN-a2b (5 mU b.i.d), arbidol (200 mg t.i.d) or the combination of both broad-spectrum antivirals. All patients had only moderate illness; none required intensive care or oxygen supplementation or intubation.
Compared with arbidol alone (27.9 days), IFN-a2b treatment, with (20.3 days) or without arbidol (21.1 days), was associated with significantly accelerated viral clearance from the respiratory tract and reduced duration of elevated blood levels of the inflammatory markers interleukin-6 and C-reactive protein, the researchers report.
With IFN-a2b, “we achieved accelerated viral clearance by about seven days, which is faster than with remdesivir, and we showed a reduction in circulating levels of inflammatory markers, which really exacerbate disease,” Dr. Fish told Reuters Health.
Age, co-morbidities and sex did not negate the effects of IFN treatment on viral clearance times or on the reduction in the inflammatory markers.
“This was an exploratory study, but I see absolutely no reason why these exploratory studies should not have relevancy. Very often they are dismissed because they are not the gold-standard randomized controlled trial, which are very difficult to do during an outbreak,” Dr. Fish commented.
She and her colleagues previously demonstrated the therapeutic benefit of interferon during the Toronto SARS outbreak of 2002 and 2003. In that study, IFN treatment seemed to speed up the resolution of lung abnormalities in SARS-infected patients.
“Interferons are broad-spectrum antivirals that should be considered as ‘first responders’ for all acute virus infections that are severe,” Dr. Fish said. “The beauty is you don’t have to know the virus. Because they are polytrophic, they target many different facets and stages of a virus’ lifecycle and in addition they muster and activate immune cells to help clear the virus.”
Just seen a GP from Newcastle On BBC News at 10 saying that people suffering from pre-existing chronic diseases such as COPD will be at greater risk if they contract with Covid virus...... I know all on this board probably know this but bringing the disease more to the attention of the public ...... do we know a possible way of reducing the risk......?
Not really big news!!!! Are you bonkers! Our Company has specifically been mentioned by the transport minister in this evenings CV update ....... absolutely huge recognition and brilliant PR
Actual spread now 40.05/40.7........the 40's are back....yes!!